DEPOSIT AGREEMENT by and among AUTOLUS THERAPEUTICS PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [●], 2018Deposit Agreement • May 10th, 2018 • Autolus Therapeutics LTD • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT, dated as of [●], 2018, by and among (i) Autolus Therapeutics plc, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
SUPPLY AGREEMENT (MB Global Contract No. [***])Confidential Treatment • May 10th, 2018 • Autolus Therapeutics LTD • Biological products, (no disgnostic substances)
This Supply Agreement (this “Agreement”) is made as of March 23, 2018, by and between Miltenyi Biotec GmbH, having an address at Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach, Germany (hereinafter referred to as “Miltenyi”), and Autolus Ltd, having an address at Forest House, 58 Wood Lane, London, W12 7RZ, UK (hereinafter referred to as “Autolus”). Miltenyi and Autolus are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENCE AGREEMENT AS AMENDED ON 28 MARCH 2018Confidential Treatment • May 10th, 2018 • Autolus Therapeutics LTD • Biological products, (no disgnostic substances) • England
THIS AGREEMENT was made as of 25 September 2014 (the “Effective Date”), was amended as of 2 March 2016 (the “Amendment Date”), and is amended and restated as of 28 March 2018 (the “Second Amendment Date”)
